UroGen Pharma Ltd. Files 10-K/A Amendment for Fiscal Year Ended Dec 31, 2023

TL;DR

<b>UroGen Pharma Ltd. has filed an amended 10-K for FY2023, indicating its status as a smaller reporting company.</b>

AI Summary

UroGen Pharma Ltd. (URGN) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. UroGen Pharma Ltd. filed an amended 10-K report for the fiscal year ending December 31, 2023. The company is incorporated in Israel and its principal executive offices are located in Princeton, NJ. UroGen Pharma Ltd. is registered under the ticker URGN on The Nasdaq Stock Market LLC. The filing indicates the company is not a well-known seasoned issuer. UroGen Pharma Ltd. is classified as a non-accelerated filer and a smaller reporting company.

Why It Matters

For investors and stakeholders tracking UroGen Pharma Ltd., this filing contains several important signals. This amended filing provides updated information for the fiscal year 2023, which is crucial for investors to assess the company's financial health and strategic direction. The classification as a smaller reporting company suggests specific disclosure requirements and potential investor considerations regarding market capitalization and reporting obligations.

Risk Assessment

Risk Level: low — UroGen Pharma Ltd. shows low risk based on this filing. The filing is an amendment to a previous report, suggesting that the core business and financial information is largely established, and this amendment likely contains clarifications or minor updates rather than significant new risks.

Analyst Insight

Review the specific changes in the 10-K/A filing to understand any updated disclosures or financial adjustments made by UroGen Pharma Ltd. for the fiscal year 2023.

Key Numbers

• 2023-12-31 — Fiscal Year End (Report period)
• 001-38079 — Commission File Number (SEC registration)
• NIS 0.01 — Par Value (Ordinary Shares)

Key Players & Entities

• UroGen Pharma Ltd. (company) — Filer name
• URGN (company) — Trading Symbol
• The Nasdaq Stock Market LLC (company) — Exchange where shares are registered
• 2023-12-31 (date) — Fiscal year end
• 2024-04-29 (date) — Filing date
• Israel (location) — Jurisdiction of incorporation
• Princeton, NJ (location) — Principal executive offices

FAQ

Risk Factors

• Reporting Status [low — regulatory]: The company is classified as a non-accelerated filer and a smaller reporting company, indicating specific regulatory reporting requirements.

Industry Context

UroGen Pharma Ltd. operates in the pharmaceutical preparations industry, focusing on urologic conditions.

Regulatory Implications

The company is subject to SEC regulations for public reporting, including the filing of annual reports (10-K) and amendments (10-K/A).

What Investors Should Do

1. Analyze the specific amendments made in the 10-K/A filing for any material changes.
2. Review UroGen Pharma Ltd.'s classification as a smaller reporting company and its implications.
3. Monitor future filings for updates on financial performance and strategic developments.

Key Dates

• 2023-12-31: Fiscal Year End — The period covered by the amended 10-K filing.
• 2024-04-29: Filing Date — Date the amended 10-K was submitted to the SEC.

Year-Over-Year Comparison

This is an amended 10-K filing (10-K/A), indicating updates or corrections to a previously submitted annual report for the fiscal year ended December 31, 2023.

Key Financial Figures

• $1.8B — st spine surgery business in the world ($1.8B). He served in this capacity from Augus

Filing Documents

• urgn20231231_10ka.htm (10-K/A) — 424KB
• ex_653285.htm (EX-31.3) — 4KB
• ex_653286.htm (EX-31.4) — 4KB
• actualceodirectcompensat.jpg (GRAPHIC) — 25KB
• 0001437749-24-013504.txt (&nbsp;) — 757KB
• urgn-20231231.xsd (EX-101.SCH) — 3KB
• urgn-20231231_def.xml (EX-101.DEF) — 17KB
• urgn-20231231_lab.xml (EX-101.LAB) — 23KB
• urgn-20231231_pre.xml (EX-101.PRE) — 18KB
• urgn20231231_10ka_htm.xml (XML) — 7KB

Executive Compensation

Executive Compensation. 6 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 22 Item 13. Certain Relationships and Related Transactions and Director Independence. 25 Item 14. Principal Accountant Fees and Services. 27 PART IV . Item 15. Exhibits, Financial Statement Schedules. 28 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance. Information Concerning Our Directors Our Board currently consists of eight directors. The brief biographies below include information, as of the date of this Form 10-K/A, regarding the specific and particular experience, qualifications, attributes or skills of each director that qualify such director to serve on our Board. Name Age Position Held With the Company Arie Belldegrun, M.D., FACS 74 Chair of the Board Elizabeth Barrett 61 Director and Chief Executive Officer Cynthia M. Butitta 69 Director Fred E. Cohen, M.D., D.Phil. 67 Director Stuart Holden, M.D. 81 Director James A. Robinson, Jr 54 Director Leana Wen, M.D., M.SC. 41 Director Daniel G. Wildman 67 Director Arie Belldegrun, M.D., FACS has served as our Chair since December 2012. Dr. Belldegrun is a co-founder of Allogene Therapeutics, a public biopharmaceutical company, and has served as Executive Chairman of its board of directors since November 2017. From March 2014 until October 2017 Dr. Belldegrun served as the President and Chief Executive Officer of Kite Pharma, Inc. and as a member of its board of directors from June 2009 until October 2017. Dr. Belldegrun currently serves as Chairman of Bellco Capital LLC (since 2004); Chairman and Partner of Two River (since June 2009); Co-chairman of Breakthrough Properties LLC and Breakthrough Services, L.L.C. (since April 2019); Chairman of Kronos Bio (since November 2017); Co-chairman of Symbiotic Capital (since June 2023); Director of Gingko Bioworks (since September 2021); and Director of ByHeart, Inc. (since October 2019). Dr. Belldegrun is also Senior Managing Director of Vida Ventures, LLC (since November 2017). Dr. Belldegrun is a Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Founder and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, Dr. Bel

Executive Compensation

Item 11. Executive Compensation.

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION We are a "smaller reporting company" under Item 10 of Regulation S-K promulgated under the Exchange Act and the following compensation disclosure is intended to comply with the requirements applicable to smaller reporting companies. Although the rules allow us to provide less detail about our executive compensation program than companies that are not smaller reporting companies, our Compensation Committee is committed to providing the informat